Effects of Ribavirin and dexamethasone on clinical outcome of Crimean-Congo Hemorrhagic Fever

Effects of only Ribavirin and Additional Therapy with dexamethasone on clinical outcome Among Patients With severe Crimean-Congo Hemorrhagic Fever

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015120525378N1

Enrollment

Registered

2016-05-18

Start date

2015-07-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crimean-Congo Hemorrhagic Fever. Central Asian haemorrhagic fever

Interventions

Intervention 1: Control group: ribavirin 30 milligram per kilogram for the first dose then 16 milligram per kilogram every 6 hours for 4 days then 8 milligram per kilogram every eight hours for six da

Treatment - Drugs

Control group: ribavirin 30 milligram per kilogram for the first dose then 16 milligram per kilogram every 6 hours for 4 days then 8 milligram per kilogram every eight hours for six days

Intervention group: ribavirin 30 milligram per killogram for the first dose, then 16 milligram per killogram every 6 hours for 4 days, then 8 milligram per killogram every eight hours for six days in

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: severe thrombocytopenia (plt<20000); petechiae, ecchymosis or bleeding; low serum levels of fibrinogen (=120 mg/dl); ptt=60; Loss of consciousness Exclusion criteria: no sever CCHF (base on SSI criteria); pregnancy; underlying disorder; receive Immunosuppressive drugs; Patients who do not have the necessary cooperation; All patients who received any antiviral , blood or blood products from the onset of symptoms to admission to Boo_Ali hospital; All patients who have not confirmed CCHF

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Mortality rate. Timepoint: After intervention. Method of measurement: Based on the observed and recorded data.;Need of blood products. Timepoint: After Intervention. Method of measurement: According to transfused units.;Recovery rate. Timepoint: After intervention. Method of measurement: Based on the observed and recorded data.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShahab-Aldin Mashaie

Zahedan University of Medical Sciences

shahabhsm@yahoo.com+98 54 3341 5705

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026